The clinical burden of disease resulting from human papillomavirus (HPV) infection is
substantial and extends from genital warts to cytologic abnormalities to cervical, vaginal, and …

Human papillomavirus (HPV), a sexually transmitted infection and the etiologic cause of
genital warts and cervical cancer, is highly prevalent in sexually active men and women …

Human papillomavirus (HPV) currently infects approximately 20 million people in the United
States. An effective new vaccine has been approved for girls and young women aged 9 to …

In pediatrics, as in all of medicine, prevention of illness is our primary responsibility.
Although HPV vaccine is one of the safest and most effective vaccines we have and is one of …

The lifetime risk of human papillomavirus (HPV) infection exceeds 50%. HPV infection
causes> 550,000 cases of cervical and anogenital cancer worldwide annually. Infection also …

It has been estimated that genital human papillomavirus (HPV) is the most common sexually
transmitted infection in the US. Nononcogenic types, such as HPV type 6 (HPV‐6) and HPV …

Human papillomavirus (HPV) is the most common sexually transmitted infection in the
United States, and persistent HPV infection is strongly associated with risk of cervical cancer …

Vaccines that protect against infection with the types of human papillomavirus (HPV)
commonly associated with cervical cancer (HPV 16 and 18) and genital warts (HPV 6 and …

BY ANY MEASURE, GENITAL HUMAN PAPILLOMAVIRUS (HPV) infection and HPV-
associated cervical can-cer are significant national and global public health concerns. An …

Vaccines that prevent infection with human papillomavirus (HPV) could have a tremendous
public health impact. In June of 2006, the Food and Drug Administration (FDA) approved an …